SCHEMBL2452887

SCHEMBL2452887

CC(C)(C)N(Cc1ccc(F)c(NC(=O)C(F)(F)F)c1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
HTT P42858 2/20 0.39
THRB P10828 2/20 0.39
GAA P10253 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
PARP1 P09874 2/20 0.39
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK3 Q15120 1/20 0.37
PDK4 Q16654 1/20 0.37
RIPK1 Q13546 1/20 0.37
RAB9A P51151 1/20 0.36
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36
SOAT1 P35610 1/20 0.35
NR1H2 P55055 1/20 0.35
EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6988369 0.77 CYP4F2 (0.43) ALDH1A1L3MBTL1HTTTHRBGAA
SCHEMBL23148222 0.76 RIPK1 (0.44) ALDH1A1L3MBTL1HTTMEN1KMT2A
SCHEMBL2454761 0.76 MEN1 (0.42) ALDH1A1L3MBTL1HTTMEN1KMT2A
SCHEMBL1362285 0.76 CYP1A2 (0.48) ALDH1A1L3MBTL1HTTMEN1KMT2A
SCHEMBL2854378 0.75 EPHX2 (0.40) ALDH1A1L3MBTL1HTTTHRBGAA
SCHEMBL2854380 0.72 MAPT (0.48) ALDH1A1L3MBTL1HTTTHRBGAA
SCHEMBL2457267 0.72 LMNA (0.44) ALDH1A1L3MBTL1HTTMEN1KMT2A
SCHEMBL14515393 0.70 ALDH1A1 (0.52) ALDH1A1L3MBTL1HTTTHRBGAA
SCHEMBL23832906 0.70 MEN1 (0.40) ALDH1A1L3MBTL1HTTMEN1KMT2A
SCHEMBL6987902 0.69 CYP4F2 (0.48) ALDH1A1L3MBTL1HTTTHRBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-29 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 ALDH1A1 625/4885L3MBTL1 3082/4885HTT 4218/4885
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NR3C2, RAF1 ALDH1A1 1374/4885L3MBTL1 3976/4885HTT 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.